Janus Henderson Group PLC Acquires 362,276 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Janus Henderson Group PLC increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2,397.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 377,384 shares of the company's stock after acquiring an additional 362,276 shares during the quarter. Janus Henderson Group PLC owned approximately 0.58% of Kymera Therapeutics worth $15,197,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Blue Trust Inc. raised its holdings in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after buying an additional 270 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares in the last quarter. KBC Group NV raised its holdings in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after acquiring an additional 752 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Kymera Therapeutics by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company's stock worth $552,000 after acquiring an additional 1,311 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in Kymera Therapeutics by 15.5% in the 4th quarter. Arizona State Retirement System now owns 11,221 shares of the company's stock valued at $451,000 after acquiring an additional 1,503 shares in the last quarter.

Insider Activity at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. This represents a 3.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,659 shares of company stock valued at $324,567. Insiders own 16.01% of the company's stock.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded down $1.30 during mid-day trading on Wednesday, reaching $30.14. 365,263 shares of the company traded hands, compared to its average volume of 561,601. The firm has a market cap of $1.96 billion, a PE ratio of -12.88 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The company's 50 day moving average price is $29.23 and its 200-day moving average price is $36.76.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm's quarterly revenue was up 114.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.69) EPS. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KYMR. HC Wainwright boosted their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Guggenheim reiterated a "buy" rating and set a $52.00 price target on shares of Kymera Therapeutics in a report on Monday, May 12th. Citigroup began coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Kymera Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $55.00 target price for the company. Finally, Stephens reiterated an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $55.25.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.